Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Gewählte Publikation:

SHR Neuro Krebs Kardio Lipid Stoffw Microb

Keil, F; Selzer, E; Berghold, A; Reinisch, S; Kapp, KS; De Vries, A; Greil, R; Bachtiary, B; Tinchon, C; Anderhuber, W; Burian, M; Kasparek, AK; Elsäßer, W; Kainz, H; Riedl, R; Kopp, M; Kornek, G.
Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
Eur J Cancer. 2013; 49(2):352-359 Doi: 10.1016/j.ejca.2012.08.004
Web of Science PubMed FullText FullText_MUG

 

Co-Autor*innen der Med Uni Graz
Anderhuber Wolfgang
Berghold Andrea
Kapp Karin S.
Kasparek Anne-Katrin
Reinisch Sabine
Riedl Regina
Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:
Purpose: To determine the efficacy and feasibility of induction chemotherapy (ICT) with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy and cetuximab (C) in patients with locally advanced head and neck cancer. Patients and methods: Forty-nine previously untreated patients with local advanced stage III and IV squamous cell carcinoma of the head and neck (SCCHN) received three courses of ICT consisting of docetaxel 75 mg/m(2) day 1, cisplatin 75 mg/m(2) day 1 and infusional 5-fluorouracil 750 mg/m(2)/day on days 1-5 followed by radiotherapy plus C at 250 mg/m(2)/week (after an initial loading dose of 400 mg/m(2)). Results: After completion of ICT 44 of 49 patients received radiotherapy plus C. Three months after therapy completion tumour response was observed in 33 patients and after two years, 25 patients were in complete remission (CR). The most common grade 4 toxicity during the whole treatment period was dermatitis (30%), followed by mucositis (27%) and neutropenia (17%) without fever. One toxic related death was observed during ICT. Two-year progression-free survival (PFS) rate was 59% and two-year overall survival (OS) rate was 63%, respectively. Conclusion: Concurrent radiotherapy plus C after three courses of ICT was feasible and was associated with promising CR, PFS and OS rates. Further optimisation of dose and sequence is warranted. (C) 2012 Elsevier Ltd. All rights reserved.
Find related publications in this database (using NLM MeSH Indexing)
Adult -
Aged -
Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects
Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - pathology Carcinoma, Squamous Cell - radiotherapy
Cisplatin - administration & dosage Cisplatin - adverse effects
Disease-Free Survival -
Female -
Fluorouracil - administration & dosage Fluorouracil - adverse effects
Head and Neck Neoplasms - drug therapy Head and Neck Neoplasms - pathology Head and Neck Neoplasms - radiotherapy
Humans -
Induction Chemotherapy -
Male -
Middle Aged -
Taxoids - administration & dosage Taxoids - adverse effects

Find related publications in this database (Keywords)
SSCHN
Induction chemotherapy
Radiotherapy
Cetuximab
© Med Uni Graz Impressum